Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
1.38
Dollar change
-0.00
Percentage change
-0.14
%
Index- P/E- EPS (ttm)-1.50 Insider Own12.06% Shs Outstand15.97M Perf Week28.97%
Market Cap22.04M Forward P/E- EPS next Y-1.16 Insider Trans0.00% Shs Float14.04M Perf Month15.97%
Income-23.96M PEG- EPS next Q-0.45 Inst Own18.71% Short Float0.12% Perf Quarter21.05%
Sales0.00M P/S- EPS this Y13.67% Inst Trans4.09% Short Ratio0.35 Perf Half Y6.98%
Book/sh0.74 P/B1.86 EPS next Y10.42% ROA-88.71% Short Interest0.02M Perf Year135.86%
Cash/sh0.90 P/C1.53 EPS next 5Y- ROE-102.79% 52W Range0.47 - 1.69 Perf YTD22.12%
Dividend Est.- P/FCF- EPS past 5Y-26.70% ROI-201.87% 52W High-18.34% Beta2.17
Dividend TTM- Quick Ratio3.83 Sales past 5Y0.00% Gross Margin- 52W Low193.62% ATR (14)0.11
Dividend Ex-Date- Current Ratio3.83 EPS Y/Y TTM-61.54% Oper. Margin0.00% RSI (14)67.21 Volatility10.90% 9.36%
Employees5 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-90.31% Payout- Rel Volume1.16 Prev Close1.38
Sales Surprise- EPS Surprise-15.61% Sales Q/Q- EarningsMar 21 BMO Avg Volume48.27K Price1.38
SMA2019.03% SMA5024.83% SMA20022.88% Trades Volume55,955 Change-0.14%
Mar-21-24 01:53PM
07:43AM
Nov-09-23 04:15PM
Oct-31-23 09:00AM
Oct-24-23 12:30PM
09:00AM Loading…
Sep-27-23 09:00AM
Aug-10-23 02:19PM
Aug-09-23 04:10PM
Aug-01-23 07:30AM
Jun-13-23 01:34PM
Jun-03-23 08:27AM
May-10-23 04:39PM
Apr-24-23 12:01PM
Apr-18-23 10:15AM
Apr-04-23 12:00PM
07:30AM Loading…
Apr-03-23 07:30AM
Mar-22-23 05:08PM
Mar-15-23 07:30AM
Feb-13-23 08:52AM
Feb-10-23 01:36PM
Feb-07-23 12:21PM
Feb-06-23 07:30AM
Jan-31-23 07:30AM
Jan-09-23 07:30AM
Jan-04-23 07:30AM
Dec-08-22 07:30AM
Nov-29-22 07:30AM
Nov-27-22 07:36AM
Nov-21-22 09:11AM
Nov-09-22 04:14PM
07:30AM Loading…
Oct-20-22 07:30AM
Sep-27-22 11:41AM
07:30AM
Sep-06-22 12:50PM
07:30AM
Aug-11-22 04:01PM
Aug-02-22 10:49AM
Jul-05-22 09:22PM
May-15-22 10:12AM
May-11-22 04:01PM
May-05-22 07:30AM
Apr-11-22 07:30AM
Apr-06-22 07:30AM
Mar-30-22 04:33PM
Mar-23-22 04:01PM
Mar-08-22 06:12PM
Feb-22-22 07:30AM
Jan-05-22 04:01PM
Jan-04-22 07:30AM
Dec-10-21 11:11AM
10:11AM
09:54AM
06:45AM
Dec-09-21 06:00PM
Dec-06-21 04:45PM
Dec-02-21 04:01PM
Dec-01-21 06:30PM
Nov-19-21 09:00AM
Nov-01-21 04:02PM
Oct-27-21 07:30AM
Oct-22-21 04:05PM
Oct-20-21 04:57PM
Oct-19-21 07:14PM
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.